nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyproterone acetate—CYP19A1—esophageal cancer	0.803	1	CbGaD
Cyproterone acetate—Coma hepatic—Capecitabine—esophageal cancer	0.00541	0.045	CcSEcCtD
Cyproterone acetate—Retinal vein thrombosis—Methotrexate—esophageal cancer	0.00481	0.0401	CcSEcCtD
Cyproterone acetate—Azoospermia—Cisplatin—esophageal cancer	0.00342	0.0285	CcSEcCtD
Cyproterone acetate—Phlebitis—Carboplatin—esophageal cancer	0.00264	0.022	CcSEcCtD
Cyproterone acetate—Hepatic cirrhosis—Methotrexate—esophageal cancer	0.00263	0.0219	CcSEcCtD
Cyproterone acetate—Thromboembolic event—Capecitabine—esophageal cancer	0.00252	0.021	CcSEcCtD
Cyproterone acetate—Infertility—Methotrexate—esophageal cancer	0.00193	0.0161	CcSEcCtD
Cyproterone acetate—Azoospermia—Methotrexate—esophageal cancer	0.00187	0.0156	CcSEcCtD
Cyproterone acetate—Thromboembolic event—Methotrexate—esophageal cancer	0.00187	0.0156	CcSEcCtD
Cyproterone acetate—Nodule—Methotrexate—esophageal cancer	0.00172	0.0143	CcSEcCtD
Cyproterone acetate—Blindness—Cisplatin—esophageal cancer	0.00166	0.0138	CcSEcCtD
Cyproterone acetate—Depressed mood—Capecitabine—esophageal cancer	0.00152	0.0126	CcSEcCtD
Cyproterone acetate—Optic neuritis—Cisplatin—esophageal cancer	0.0015	0.0125	CcSEcCtD
Cyproterone acetate—Ascites—Capecitabine—esophageal cancer	0.00149	0.0124	CcSEcCtD
Cyproterone acetate—Retinal disorder—Methotrexate—esophageal cancer	0.00141	0.0118	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—SNAI2—esophageal cancer	0.00131	0.017	CbGpPWpGaD
Cyproterone acetate—AR—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.00121	0.0157	CbGpPWpGaD
Cyproterone acetate—Hirsutism—Capecitabine—esophageal cancer	0.00117	0.00972	CcSEcCtD
Cyproterone acetate—NR3C1—Nuclear Receptors—NR1I2—esophageal cancer	0.00116	0.0151	CbGpPWpGaD
Cyproterone acetate—Pulmonary fibrosis—Methotrexate—esophageal cancer	0.00115	0.00956	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—PHB—esophageal cancer	0.00114	0.0148	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Endogenous sterols—CYP1B1—esophageal cancer	0.00113	0.0147	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—PRDX1—esophageal cancer	0.00112	0.0145	CbGpPWpGaD
Cyproterone acetate—Embolism—Capecitabine—esophageal cancer	0.00106	0.0088	CcSEcCtD
Cyproterone acetate—Encephalopathy—Capecitabine—esophageal cancer	0.00106	0.0088	CcSEcCtD
Cyproterone acetate—Tenderness—Cisplatin—esophageal cancer	0.00105	0.00878	CcSEcCtD
Cyproterone acetate—Aphasia—Capecitabine—esophageal cancer	0.00105	0.00871	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CRTC1—esophageal cancer	0.00103	0.0134	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.000985	0.0128	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—PHB—esophageal cancer	0.000981	0.0127	CbGpPWpGaD
Cyproterone acetate—Hypercalcaemia—Capecitabine—esophageal cancer	0.000976	0.00813	CcSEcCtD
Cyproterone acetate—Hepatomegaly—Capecitabine—esophageal cancer	0.000958	0.00798	CcSEcCtD
Cyproterone acetate—Thrombosis—Capecitabine—esophageal cancer	0.000958	0.00798	CcSEcCtD
Cyproterone acetate—NR3C1—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.000923	0.012	CbGpPWpGaD
Cyproterone acetate—NR3C1—Nuclear Receptor transcription pathway—NR1I2—esophageal cancer	0.00092	0.0119	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.000916	0.0119	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.000911	0.0118	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—KRT14—esophageal cancer	0.000908	0.0118	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.000904	0.0117	CbGpPWpGaD
Cyproterone acetate—Osteoporosis—Methotrexate—esophageal cancer	0.000901	0.0075	CcSEcCtD
Cyproterone acetate—Body temperature increased—Carboplatin—esophageal cancer	0.000885	0.00737	CcSEcCtD
Cyproterone acetate—Fluid retention—Cisplatin—esophageal cancer	0.000873	0.00727	CcSEcCtD
Cyproterone acetate—CYP19A1—Tryptophan metabolism—ALDH2—esophageal cancer	0.000859	0.0111	CbGpPWpGaD
Cyproterone acetate—Polyp—Methotrexate—esophageal cancer	0.00083	0.00691	CcSEcCtD
Cyproterone acetate—Vaginal discharge—Methotrexate—esophageal cancer	0.00083	0.00691	CcSEcCtD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.000799	0.0104	CbGpPWpGaD
Cyproterone acetate—Encephalopathy—Methotrexate—esophageal cancer	0.000786	0.00655	CcSEcCtD
Cyproterone acetate—Embolism—Methotrexate—esophageal cancer	0.000786	0.00655	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.000779	0.0101	CbGpPWpGaD
Cyproterone acetate—Aphasia—Methotrexate—esophageal cancer	0.000778	0.00648	CcSEcCtD
Cyproterone acetate—Phlebitis—Cisplatin—esophageal cancer	0.000775	0.00646	CcSEcCtD
Cyproterone acetate—Cyst—Methotrexate—esophageal cancer	0.000755	0.00629	CcSEcCtD
Cyproterone acetate—Skin discolouration—Capecitabine—esophageal cancer	0.000751	0.00625	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX1—esophageal cancer	0.000747	0.0097	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000743	0.00964	CbGpPWpGaD
Cyproterone acetate—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00074	0.00616	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.000715	0.00929	CbGpPWpGaD
Cyproterone acetate—Gait disturbance—Capecitabine—esophageal cancer	0.000695	0.00579	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000681	0.00568	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—SFN—esophageal cancer	0.000679	0.00881	CbGpPWpGaD
Cyproterone acetate—Pulmonary embolism—Capecitabine—esophageal cancer	0.000678	0.00565	CcSEcCtD
Cyproterone acetate—Injection site reaction—Capecitabine—esophageal cancer	0.000674	0.00562	CcSEcCtD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000653	0.00848	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Tryptophan metabolism—CYP1B1—esophageal cancer	0.000651	0.00845	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000644	0.00836	CbGpPWpGaD
Cyproterone acetate—Fluid retention—Capecitabine—esophageal cancer	0.000644	0.00536	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Cisplatin—esophageal cancer	0.000626	0.00521	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—XRCC3—esophageal cancer	0.000624	0.0081	CbGpPWpGaD
Cyproterone acetate—Neoplasm—Capecitabine—esophageal cancer	0.000613	0.00511	CcSEcCtD
Cyproterone acetate—NR3C1—Endoderm Differentiation—SOX2—esophageal cancer	0.000606	0.00786	CbGpPWpGaD
Cyproterone acetate—Breast disorder—Cisplatin—esophageal cancer	0.000603	0.00503	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000601	0.00501	CcSEcCtD
Cyproterone acetate—Abnormal vision—Capecitabine—esophageal cancer	0.000591	0.00493	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—esophageal cancer	0.000591	0.00767	CbGpPWpGaD
Cyproterone acetate—Phlebitis—Capecitabine—esophageal cancer	0.000571	0.00476	CcSEcCtD
Cyproterone acetate—Sleep disorder—Capecitabine—esophageal cancer	0.000569	0.00474	CcSEcCtD
Cyproterone acetate—Thrombophlebitis—Capecitabine—esophageal cancer	0.000569	0.00474	CcSEcCtD
Cyproterone acetate—Diabetes mellitus—Capecitabine—esophageal cancer	0.000566	0.00471	CcSEcCtD
Cyproterone acetate—Pancreatitis—Cisplatin—esophageal cancer	0.000566	0.00471	CcSEcCtD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000563	0.00731	CbGpPWpGaD
Cyproterone acetate—Sweating increased—Cisplatin—esophageal cancer	0.000562	0.00468	CcSEcCtD
Cyproterone acetate—Skin discolouration—Methotrexate—esophageal cancer	0.000559	0.00466	CcSEcCtD
Cyproterone acetate—Glossitis—Methotrexate—esophageal cancer	0.000548	0.00456	CcSEcCtD
Cyproterone acetate—Hepatic failure—Capecitabine—esophageal cancer	0.000548	0.00456	CcSEcCtD
Cyproterone acetate—Haemolytic anaemia—Capecitabine—esophageal cancer	0.000545	0.00454	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—ADCYAP1—esophageal cancer	0.000543	0.00704	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—XRCC3—esophageal cancer	0.000537	0.00697	CbGpPWpGaD
Cyproterone acetate—Libido decreased—Capecitabine—esophageal cancer	0.000531	0.00442	CcSEcCtD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000529	0.00687	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.000529	0.00687	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000526	0.00683	CbGpPWpGaD
Cyproterone acetate—Hot flush—Capecitabine—esophageal cancer	0.000526	0.00438	CcSEcCtD
Cyproterone acetate—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000522	0.00435	CcSEcCtD
Cyproterone acetate—Menopausal symptoms—Capecitabine—esophageal cancer	0.000522	0.00435	CcSEcCtD
Cyproterone acetate—CYP19A1—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000519	0.00674	CbGpPWpGaD
Cyproterone acetate—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000507	0.00423	CcSEcCtD
Cyproterone acetate—Renal failure—Cisplatin—esophageal cancer	0.000506	0.00421	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—SFN—esophageal cancer	0.000505	0.00656	CbGpPWpGaD
Cyproterone acetate—Pulmonary embolism—Methotrexate—esophageal cancer	0.000505	0.00421	CcSEcCtD
Cyproterone acetate—Myocardial infarction—Cisplatin—esophageal cancer	0.000504	0.0042	CcSEcCtD
Cyproterone acetate—Cardiac failure—Capecitabine—esophageal cancer	0.000504	0.0042	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000502	0.00418	CcSEcCtD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000502	0.00651	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—HIF1A—esophageal cancer	0.000501	0.0065	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CALR—esophageal cancer	0.000496	0.00644	CbGpPWpGaD
Cyproterone acetate—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.000488	0.00407	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000487	0.00405	CcSEcCtD
Cyproterone acetate—Migraine—Capecitabine—esophageal cancer	0.000485	0.00404	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—ADH7—esophageal cancer	0.000484	0.00628	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—KDR—esophageal cancer	0.000479	0.00622	CbGpPWpGaD
Cyproterone acetate—Mood swings—Capecitabine—esophageal cancer	0.000466	0.00388	CcSEcCtD
Cyproterone acetate—Coma—Methotrexate—esophageal cancer	0.000461	0.00384	CcSEcCtD
Cyproterone acetate—Blood creatinine increased—Capecitabine—esophageal cancer	0.000461	0.00384	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.000461	0.00598	CbGpPWpGaD
Cyproterone acetate—Neoplasm—Methotrexate—esophageal cancer	0.000456	0.0038	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Capecitabine—esophageal cancer	0.000454	0.00379	CcSEcCtD
Cyproterone acetate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000454	0.00378	CcSEcCtD
Cyproterone acetate—Gynaecomastia—Methotrexate—esophageal cancer	0.000452	0.00376	CcSEcCtD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—NOTCH1—esophageal cancer	0.000451	0.00586	CbGpPWpGaD
Cyproterone acetate—Visual impairment—Cisplatin—esophageal cancer	0.000445	0.00371	CcSEcCtD
Cyproterone acetate—Breast disorder—Capecitabine—esophageal cancer	0.000445	0.00371	CcSEcCtD
Cyproterone acetate—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000443	0.00369	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—CYP26A1—esophageal cancer	0.000435	0.00565	CbGpPWpGaD
Cyproterone acetate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000434	0.00362	CcSEcCtD
Cyproterone acetate—Muscular weakness—Capecitabine—esophageal cancer	0.000434	0.00362	CcSEcCtD
Cyproterone acetate—Eye disorder—Cisplatin—esophageal cancer	0.000432	0.0036	CcSEcCtD
Cyproterone acetate—AR—FOXA1 transcription factor network—CREBBP—esophageal cancer	0.000431	0.0056	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000427	0.00554	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.000425	0.00552	CbGpPWpGaD
Cyproterone acetate—Asthma—Capecitabine—esophageal cancer	0.000425	0.00354	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—ADH1B—esophageal cancer	0.000425	0.00551	CbGpPWpGaD
Cyproterone acetate—Thrombophlebitis—Methotrexate—esophageal cancer	0.000423	0.00353	CcSEcCtD
Cyproterone acetate—Diabetes mellitus—Methotrexate—esophageal cancer	0.000421	0.00351	CcSEcCtD
Cyproterone acetate—Immune system disorder—Cisplatin—esophageal cancer	0.000417	0.00348	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Cisplatin—esophageal cancer	0.000416	0.00347	CcSEcCtD
Cyproterone acetate—Sweating increased—Capecitabine—esophageal cancer	0.000414	0.00345	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.000411	0.00533	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.000411	0.00533	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—CREBBP—esophageal cancer	0.000409	0.00531	CbGpPWpGaD
Cyproterone acetate—Alopecia—Cisplatin—esophageal cancer	0.000408	0.0034	CcSEcCtD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—RB1—esophageal cancer	0.000408	0.00529	CbGpPWpGaD
Cyproterone acetate—Hepatic failure—Methotrexate—esophageal cancer	0.000408	0.0034	CcSEcCtD
Cyproterone acetate—Malnutrition—Cisplatin—esophageal cancer	0.000402	0.00335	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.000396	0.00514	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—CYP26A1—esophageal cancer	0.000395	0.00512	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000389	0.00505	CbGpPWpGaD
Cyproterone acetate—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000388	0.00323	CcSEcCtD
Cyproterone acetate—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000388	0.00323	CcSEcCtD
Cyproterone acetate—Weight increased—Capecitabine—esophageal cancer	0.000387	0.00323	CcSEcCtD
Cyproterone acetate—Weight decreased—Capecitabine—esophageal cancer	0.000385	0.00321	CcSEcCtD
Cyproterone acetate—Hyperglycaemia—Capecitabine—esophageal cancer	0.000384	0.0032	CcSEcCtD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—CREBBP—esophageal cancer	0.000376	0.00488	CbGpPWpGaD
Cyproterone acetate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000374	0.00311	CcSEcCtD
Cyproterone acetate—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000374	0.00311	CcSEcCtD
Cyproterone acetate—Ill-defined disorder—Cisplatin—esophageal cancer	0.000373	0.00311	CcSEcCtD
Cyproterone acetate—Renal failure—Capecitabine—esophageal cancer	0.000373	0.00311	CcSEcCtD
Cyproterone acetate—Myocardial infarction—Capecitabine—esophageal cancer	0.000372	0.0031	CcSEcCtD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.000372	0.00483	CbGpPWpGaD
Cyproterone acetate—Anaemia—Cisplatin—esophageal cancer	0.000372	0.0031	CcSEcCtD
Cyproterone acetate—Jaundice—Capecitabine—esophageal cancer	0.00037	0.00308	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—SMAD4—esophageal cancer	0.000367	0.00477	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTO1—esophageal cancer	0.000367	0.00476	CbGpPWpGaD
Cyproterone acetate—Malaise—Cisplatin—esophageal cancer	0.000363	0.00302	CcSEcCtD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—GSTO1—esophageal cancer	0.000362	0.0047	CbGpPWpGaD
Cyproterone acetate—Haematuria—Capecitabine—esophageal cancer	0.000362	0.00301	CcSEcCtD
Cyproterone acetate—Leukopenia—Cisplatin—esophageal cancer	0.00036	0.003	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000359	0.00299	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—RUNX3—esophageal cancer	0.00035	0.00454	CbGpPWpGaD
Cyproterone acetate—Mood swings—Methotrexate—esophageal cancer	0.000347	0.00289	CcSEcCtD
Cyproterone acetate—NR3C1—Endoderm Differentiation—SMAD4—esophageal cancer	0.000346	0.00449	CbGpPWpGaD
Cyproterone acetate—Haemoglobin—Capecitabine—esophageal cancer	0.000342	0.00285	CcSEcCtD
Cyproterone acetate—Hepatitis—Capecitabine—esophageal cancer	0.000341	0.00284	CcSEcCtD
Cyproterone acetate—Haemorrhage—Capecitabine—esophageal cancer	0.000341	0.00284	CcSEcCtD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00034	0.00283	CcSEcCtD
Cyproterone acetate—Liver function test abnormal—Methotrexate—esophageal cancer	0.000338	0.00282	CcSEcCtD
Cyproterone acetate—Discomfort—Cisplatin—esophageal cancer	0.000338	0.00282	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—ANXA1—esophageal cancer	0.000337	0.00438	CbGpPWpGaD
Cyproterone acetate—NR3C1—Circadian Clock—HIF1A—esophageal cancer	0.000335	0.00435	CbGpPWpGaD
Cyproterone acetate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000335	0.00279	CcSEcCtD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CASP8—esophageal cancer	0.000334	0.00433	CbGpPWpGaD
Cyproterone acetate—Breast disorder—Methotrexate—esophageal cancer	0.000331	0.00276	CcSEcCtD
Cyproterone acetate—Oedema—Cisplatin—esophageal cancer	0.000328	0.00273	CcSEcCtD
Cyproterone acetate—Visual impairment—Capecitabine—esophageal cancer	0.000328	0.00273	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—GAPDH—esophageal cancer	0.000323	0.00419	CbGpPWpGaD
Cyproterone acetate—Erythema multiforme—Capecitabine—esophageal cancer	0.000322	0.00268	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Cisplatin—esophageal cancer	0.000322	0.00268	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Cisplatin—esophageal cancer	0.000321	0.00268	CcSEcCtD
Cyproterone acetate—Tachycardia—Cisplatin—esophageal cancer	0.00032	0.00267	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—SST—esophageal cancer	0.00032	0.00415	CbGpPWpGaD
Cyproterone acetate—Skin disorder—Cisplatin—esophageal cancer	0.000319	0.00266	CcSEcCtD
Cyproterone acetate—Eye disorder—Capecitabine—esophageal cancer	0.000318	0.00265	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Cisplatin—esophageal cancer	0.000317	0.00264	CcSEcCtD
Cyproterone acetate—Asthma—Methotrexate—esophageal cancer	0.000317	0.00264	CcSEcCtD
Cyproterone acetate—Anorexia—Cisplatin—esophageal cancer	0.000313	0.00261	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—SOX2—esophageal cancer	0.000312	0.00405	CbGpPWpGaD
Cyproterone acetate—Pancreatitis—Methotrexate—esophageal cancer	0.000311	0.00259	CcSEcCtD
Cyproterone acetate—Angiopathy—Capecitabine—esophageal cancer	0.000309	0.00257	CcSEcCtD
Cyproterone acetate—Immune system disorder—Capecitabine—esophageal cancer	0.000308	0.00256	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000307	0.00256	CcSEcCtD
Cyproterone acetate—Hypotension—Cisplatin—esophageal cancer	0.000307	0.00255	CcSEcCtD
Cyproterone acetate—Chills—Capecitabine—esophageal cancer	0.000306	0.00255	CcSEcCtD
Cyproterone acetate—Alopecia—Capecitabine—esophageal cancer	0.000301	0.00251	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—SMAD4—esophageal cancer	0.000301	0.0039	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—ALDH2—esophageal cancer	0.000299	0.00388	CbGpPWpGaD
Cyproterone acetate—Mental disorder—Capecitabine—esophageal cancer	0.000298	0.00249	CcSEcCtD
Cyproterone acetate—Malnutrition—Capecitabine—esophageal cancer	0.000296	0.00247	CcSEcCtD
Cyproterone acetate—AR—FOXA1 transcription factor network—EP300—esophageal cancer	0.000294	0.00381	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CHEK2—esophageal cancer	0.000293	0.00381	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Cisplatin—esophageal cancer	0.000293	0.00244	CcSEcCtD
Cyproterone acetate—Erectile dysfunction—Methotrexate—esophageal cancer	0.000292	0.00243	CcSEcCtD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CDKN2A—esophageal cancer	0.000291	0.00378	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—ANXA1—esophageal cancer	0.00029	0.00377	CbGpPWpGaD
Cyproterone acetate—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000289	0.00241	CcSEcCtD
Cyproterone acetate—AR—Nongenotropic Androgen signaling—PIK3CA—esophageal cancer	0.000288	0.00373	CbGpPWpGaD
Cyproterone acetate—Decreased appetite—Cisplatin—esophageal cancer	0.000285	0.00238	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—GSTT1—esophageal cancer	0.000284	0.00369	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000283	0.00236	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—CREBBP—esophageal cancer	0.000282	0.00366	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—BAX—esophageal cancer	0.000282	0.00365	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Biological oxidations—CYP2A6—esophageal cancer	0.000281	0.00365	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.000279	0.00363	CbGpPWpGaD
Cyproterone acetate—AR—Notch-mediated HES/HEY network—EP300—esophageal cancer	0.000279	0.00362	CbGpPWpGaD
Cyproterone acetate—Renal failure—Methotrexate—esophageal cancer	0.000278	0.00231	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—HIF1A—esophageal cancer	0.000276	0.00359	CbGpPWpGaD
Cyproterone acetate—Ill-defined disorder—Capecitabine—esophageal cancer	0.000275	0.00229	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CYP19A1—esophageal cancer	0.000275	0.00357	CbGpPWpGaD
Cyproterone acetate—Anaemia—Capecitabine—esophageal cancer	0.000274	0.00228	CcSEcCtD
Cyproterone acetate—NR3C1—Circadian Clock—CREBBP—esophageal cancer	0.000274	0.00355	CbGpPWpGaD
Cyproterone acetate—Sweating—Methotrexate—esophageal cancer	0.000271	0.00226	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Cisplatin—esophageal cancer	0.00027	0.00225	CcSEcCtD
Cyproterone acetate—Haematuria—Methotrexate—esophageal cancer	0.000269	0.00224	CcSEcCtD
Cyproterone acetate—Malaise—Capecitabine—esophageal cancer	0.000267	0.00223	CcSEcCtD
Cyproterone acetate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000267	0.00222	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—PTGS1—esophageal cancer	0.000267	0.00346	CbGpPWpGaD
Cyproterone acetate—Syncope—Capecitabine—esophageal cancer	0.000266	0.00221	CcSEcCtD
Cyproterone acetate—Leukopenia—Capecitabine—esophageal cancer	0.000265	0.00221	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.000265	0.00344	CbGpPWpGaD
Cyproterone acetate—Loss of consciousness—Capecitabine—esophageal cancer	0.000261	0.00217	CcSEcCtD
Cyproterone acetate—Body temperature increased—Cisplatin—esophageal cancer	0.000259	0.00216	CcSEcCtD
Cyproterone acetate—Cough—Capecitabine—esophageal cancer	0.000259	0.00215	CcSEcCtD
Cyproterone acetate—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—EP300—esophageal cancer	0.000256	0.00332	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000256	0.00332	CbGpPWpGaD
Cyproterone acetate—NR3C1—Endoderm Differentiation—NOTCH1—esophageal cancer	0.000255	0.00331	CbGpPWpGaD
Cyproterone acetate—Haemoglobin—Methotrexate—esophageal cancer	0.000255	0.00212	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TGFBR2—esophageal cancer	0.000254	0.0033	CbGpPWpGaD
Cyproterone acetate—Haemorrhage—Methotrexate—esophageal cancer	0.000253	0.00211	CcSEcCtD
Cyproterone acetate—Hepatitis—Methotrexate—esophageal cancer	0.000253	0.00211	CcSEcCtD
Cyproterone acetate—AR—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.000253	0.00329	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—esophageal cancer	0.000252	0.00328	CbGpPWpGaD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000251	0.00209	CcSEcCtD
Cyproterone acetate—Discomfort—Capecitabine—esophageal cancer	0.000249	0.00208	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—ABL1—esophageal cancer	0.000249	0.00323	CbGpPWpGaD
Cyproterone acetate—AR—Coregulation of Androgen receptor activity—CCND1—esophageal cancer	0.000246	0.00319	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CREBBP—esophageal cancer	0.000246	0.00319	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—RB1—esophageal cancer	0.000245	0.00318	CbGpPWpGaD
Cyproterone acetate—Visual impairment—Methotrexate—esophageal cancer	0.000244	0.00203	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000243	0.00315	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—SST—esophageal cancer	0.000242	0.00315	CbGpPWpGaD
Cyproterone acetate—Oedema—Capecitabine—esophageal cancer	0.000242	0.00202	CcSEcCtD
Cyproterone acetate—Hypersensitivity—Cisplatin—esophageal cancer	0.000242	0.00201	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—SMAD4—esophageal cancer	0.000241	0.00312	CbGpPWpGaD
Cyproterone acetate—Erythema multiforme—Methotrexate—esophageal cancer	0.00024	0.002	CcSEcCtD
Cyproterone acetate—Shock—Capecitabine—esophageal cancer	0.000238	0.00198	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Capecitabine—esophageal cancer	0.000237	0.00198	CcSEcCtD
Cyproterone acetate—Eye disorder—Methotrexate—esophageal cancer	0.000237	0.00197	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Capecitabine—esophageal cancer	0.000237	0.00197	CcSEcCtD
Cyproterone acetate—Tachycardia—Capecitabine—esophageal cancer	0.000236	0.00197	CcSEcCtD
Cyproterone acetate—Asthenia—Cisplatin—esophageal cancer	0.000235	0.00196	CcSEcCtD
Cyproterone acetate—Skin disorder—Capecitabine—esophageal cancer	0.000235	0.00196	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—esophageal cancer	0.000234	0.00304	CbGpPWpGaD
Cyproterone acetate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000234	0.00195	CcSEcCtD
Cyproterone acetate—Anorexia—Capecitabine—esophageal cancer	0.000231	0.00192	CcSEcCtD
Cyproterone acetate—Angiopathy—Methotrexate—esophageal cancer	0.00023	0.00192	CcSEcCtD
Cyproterone acetate—Immune system disorder—Methotrexate—esophageal cancer	0.000229	0.00191	CcSEcCtD
Cyproterone acetate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000228	0.0019	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—BAX—esophageal cancer	0.000228	0.00296	CbGpPWpGaD
Cyproterone acetate—Chills—Methotrexate—esophageal cancer	0.000227	0.00189	CcSEcCtD
Cyproterone acetate—CYP19A1—Biological oxidations—CYP1B1—esophageal cancer	0.000227	0.00294	CbGpPWpGaD
Cyproterone acetate—Hypotension—Capecitabine—esophageal cancer	0.000226	0.00188	CcSEcCtD
Cyproterone acetate—Diarrhoea—Cisplatin—esophageal cancer	0.000225	0.00187	CcSEcCtD
Cyproterone acetate—Alopecia—Methotrexate—esophageal cancer	0.000224	0.00187	CcSEcCtD
Cyproterone acetate—CYP19A1—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000224	0.0029	CbGpPWpGaD
Cyproterone acetate—Mental disorder—Methotrexate—esophageal cancer	0.000222	0.00185	CcSEcCtD
Cyproterone acetate—Malnutrition—Methotrexate—esophageal cancer	0.000221	0.00184	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—esophageal cancer	0.000219	0.00284	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000219	0.00284	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Capecitabine—esophageal cancer	0.000216	0.0018	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—ABL1—esophageal cancer	0.000214	0.00278	CbGpPWpGaD
Cyproterone acetate—Dyspepsia—Capecitabine—esophageal cancer	0.000213	0.00177	CcSEcCtD
Cyproterone acetate—Decreased appetite—Capecitabine—esophageal cancer	0.00021	0.00175	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—NR1I2—esophageal cancer	0.00021	0.00272	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000209	0.00174	CcSEcCtD
Cyproterone acetate—Vomiting—Cisplatin—esophageal cancer	0.000209	0.00174	CcSEcCtD
Cyproterone acetate—Fatigue—Capecitabine—esophageal cancer	0.000209	0.00174	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—SMAD4—esophageal cancer	0.000207	0.00269	CbGpPWpGaD
Cyproterone acetate—Rash—Cisplatin—esophageal cancer	0.000207	0.00172	CcSEcCtD
Cyproterone acetate—Constipation—Capecitabine—esophageal cancer	0.000207	0.00172	CcSEcCtD
Cyproterone acetate—Dermatitis—Cisplatin—esophageal cancer	0.000207	0.00172	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000206	0.00267	CbGpPWpGaD
Cyproterone acetate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000205	0.00171	CcSEcCtD
Cyproterone acetate—Anaemia—Methotrexate—esophageal cancer	0.000204	0.0017	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CREBBP—esophageal cancer	0.000201	0.00261	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000199	0.00259	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000199	0.00259	CbGpPWpGaD
Cyproterone acetate—Feeling abnormal—Capecitabine—esophageal cancer	0.000199	0.00166	CcSEcCtD
Cyproterone acetate—Malaise—Methotrexate—esophageal cancer	0.000199	0.00166	CcSEcCtD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—CREBBP—esophageal cancer	0.000199	0.00258	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CCND1—esophageal cancer	0.000198	0.00257	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000198	0.00165	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CDKN2A—esophageal cancer	0.000198	0.00257	CbGpPWpGaD
Cyproterone acetate—Leukopenia—Methotrexate—esophageal cancer	0.000198	0.00165	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—BAX—esophageal cancer	0.000196	0.00254	CbGpPWpGaD
Cyproterone acetate—Nausea—Cisplatin—esophageal cancer	0.000195	0.00162	CcSEcCtD
Cyproterone acetate—Cough—Methotrexate—esophageal cancer	0.000193	0.0016	CcSEcCtD
Cyproterone acetate—Urticaria—Capecitabine—esophageal cancer	0.000192	0.0016	CcSEcCtD
Cyproterone acetate—NR3C1—Regulation of Androgen receptor activity—EP300—esophageal cancer	0.000192	0.00249	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000192	0.00249	CbGpPWpGaD
Cyproterone acetate—Abdominal pain—Capecitabine—esophageal cancer	0.000191	0.00159	CcSEcCtD
Cyproterone acetate—Body temperature increased—Capecitabine—esophageal cancer	0.000191	0.00159	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.00019	0.00246	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000189	0.00245	CbGpPWpGaD
Cyproterone acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000187	0.00155	CcSEcCtD
Cyproterone acetate—NR3C1—Circadian Clock—EP300—esophageal cancer	0.000187	0.00242	CbGpPWpGaD
Cyproterone acetate—Discomfort—Methotrexate—esophageal cancer	0.000186	0.00155	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—esophageal cancer	0.000182	0.00236	CbGpPWpGaD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CCND1—esophageal cancer	0.000182	0.00236	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.00018	0.00234	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Capecitabine—esophageal cancer	0.000178	0.00148	CcSEcCtD
Cyproterone acetate—Nervous system disorder—Methotrexate—esophageal cancer	0.000177	0.00147	CcSEcCtD
Cyproterone acetate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000176	0.00147	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—CDKN1A—esophageal cancer	0.000176	0.00228	CbGpPWpGaD
Cyproterone acetate—Skin disorder—Methotrexate—esophageal cancer	0.000175	0.00146	CcSEcCtD
Cyproterone acetate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000174	0.00145	CcSEcCtD
Cyproterone acetate—Asthenia—Capecitabine—esophageal cancer	0.000174	0.00145	CcSEcCtD
Cyproterone acetate—Anorexia—Methotrexate—esophageal cancer	0.000172	0.00143	CcSEcCtD
Cyproterone acetate—Pruritus—Capecitabine—esophageal cancer	0.000171	0.00143	CcSEcCtD
Cyproterone acetate—NR3C1—Adipogenesis—HIF1A—esophageal cancer	0.000168	0.00219	CbGpPWpGaD
Cyproterone acetate—Hypotension—Methotrexate—esophageal cancer	0.000168	0.0014	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—EP300—esophageal cancer	0.000167	0.00217	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—CCND1—esophageal cancer	0.000167	0.00217	CbGpPWpGaD
Cyproterone acetate—Diarrhoea—Capecitabine—esophageal cancer	0.000166	0.00138	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000162	0.0021	CbGpPWpGaD
Cyproterone acetate—Dyspnoea—Methotrexate—esophageal cancer	0.000161	0.00134	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.00016	0.00208	CbGpPWpGaD
Cyproterone acetate—Dizziness—Capecitabine—esophageal cancer	0.00016	0.00133	CcSEcCtD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NR1I2—esophageal cancer	0.000159	0.00206	CbGpPWpGaD
Cyproterone acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MYC—esophageal cancer	0.000159	0.00206	CbGpPWpGaD
Cyproterone acetate—Dyspepsia—Methotrexate—esophageal cancer	0.000159	0.00132	CcSEcCtD
Cyproterone acetate—AR—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000157	0.00204	CbGpPWpGaD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000157	0.00203	CbGpPWpGaD
Cyproterone acetate—Decreased appetite—Methotrexate—esophageal cancer	0.000157	0.0013	CcSEcCtD
Cyproterone acetate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000155	0.0013	CcSEcCtD
Cyproterone acetate—Fatigue—Methotrexate—esophageal cancer	0.000155	0.00129	CcSEcCtD
Cyproterone acetate—Vomiting—Capecitabine—esophageal cancer	0.000154	0.00128	CcSEcCtD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—EP300—esophageal cancer	0.000154	0.002	CbGpPWpGaD
Cyproterone acetate—Rash—Capecitabine—esophageal cancer	0.000153	0.00127	CcSEcCtD
Cyproterone acetate—Dermatitis—Capecitabine—esophageal cancer	0.000152	0.00127	CcSEcCtD
Cyproterone acetate—Headache—Capecitabine—esophageal cancer	0.000152	0.00126	CcSEcCtD
Cyproterone acetate—Feeling abnormal—Methotrexate—esophageal cancer	0.000148	0.00124	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000148	0.00192	CbGpPWpGaD
Cyproterone acetate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000147	0.00123	CcSEcCtD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—HIF1A—esophageal cancer	0.000146	0.00189	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN1A—esophageal cancer	0.000144	0.00187	CbGpPWpGaD
Cyproterone acetate—Nausea—Capecitabine—esophageal cancer	0.000144	0.0012	CcSEcCtD
Cyproterone acetate—Urticaria—Methotrexate—esophageal cancer	0.000143	0.00119	CcSEcCtD
Cyproterone acetate—AR—Androgen receptor signaling pathway—EGFR—esophageal cancer	0.000143	0.00185	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—CDKN1A—esophageal cancer	0.000142	0.00185	CbGpPWpGaD
Cyproterone acetate—Body temperature increased—Methotrexate—esophageal cancer	0.000142	0.00119	CcSEcCtD
Cyproterone acetate—Abdominal pain—Methotrexate—esophageal cancer	0.000142	0.00119	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CASP8—esophageal cancer	0.000139	0.0018	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—BCL2—esophageal cancer	0.000139	0.0018	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—RB1—esophageal cancer	0.000138	0.00179	CbGpPWpGaD
Cyproterone acetate—NR3C1—Adipogenesis—RB1—esophageal cancer	0.000137	0.00178	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—EP300—esophageal cancer	0.000137	0.00178	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—EP300—esophageal cancer	0.000135	0.00176	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—MYC—esophageal cancer	0.000134	0.00174	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000134	0.00174	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000133	0.00173	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—SMG6—esophageal cancer	0.000133	0.00173	CbGpPWpGaD
Cyproterone acetate—Hypersensitivity—Methotrexate—esophageal cancer	0.000133	0.00111	CcSEcCtD
Cyproterone acetate—AR—Generic Transcription Pathway—NOTCH3—esophageal cancer	0.000132	0.00171	CbGpPWpGaD
Cyproterone acetate—Asthenia—Methotrexate—esophageal cancer	0.000129	0.00108	CcSEcCtD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000129	0.00167	CbGpPWpGaD
Cyproterone acetate—Pruritus—Methotrexate—esophageal cancer	0.000127	0.00106	CcSEcCtD
Cyproterone acetate—Diarrhoea—Methotrexate—esophageal cancer	0.000123	0.00103	CcSEcCtD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—BCL2—esophageal cancer	0.000119	0.00155	CbGpPWpGaD
Cyproterone acetate—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—esophageal cancer	0.000119	0.00155	CbGpPWpGaD
Cyproterone acetate—Dizziness—Methotrexate—esophageal cancer	0.000119	0.000992	CcSEcCtD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	0.000119	0.00155	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—CREBBP—esophageal cancer	0.000119	0.00154	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—NOTCH2—esophageal cancer	0.000118	0.00153	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000115	0.00149	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—SLC52A3—esophageal cancer	0.000115	0.00149	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—BLVRB—esophageal cancer	0.000115	0.00149	CbGpPWpGaD
Cyproterone acetate—Vomiting—Methotrexate—esophageal cancer	0.000115	0.000954	CcSEcCtD
Cyproterone acetate—Rash—Methotrexate—esophageal cancer	0.000114	0.000946	CcSEcCtD
Cyproterone acetate—Dermatitis—Methotrexate—esophageal cancer	0.000113	0.000945	CcSEcCtD
Cyproterone acetate—Headache—Methotrexate—esophageal cancer	0.000113	0.00094	CcSEcCtD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000112	0.00145	CbGpPWpGaD
Cyproterone acetate—NR3C1—AP-1 transcription factor network—TP53—esophageal cancer	0.00011	0.00143	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—EP300—esophageal cancer	0.00011	0.00142	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.000109	0.00142	CbGpPWpGaD
Cyproterone acetate—Nausea—Methotrexate—esophageal cancer	0.000107	0.000891	CcSEcCtD
Cyproterone acetate—AR—SIDS Susceptibility Pathways—EP300—esophageal cancer	0.000107	0.00139	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—CCND1—esophageal cancer	0.000102	0.00133	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000102	0.00133	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—SMG6—esophageal cancer	0.000101	0.00131	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—NR1I2—esophageal cancer	0.000101	0.00131	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NOTCH3—esophageal cancer	9.98e-05	0.0013	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—SMAD4—esophageal cancer	9.91e-05	0.00129	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	9.86e-05	0.00128	CbGpPWpGaD
Cyproterone acetate—NR3C1—Adipogenesis—CDKN1A—esophageal cancer	9.85e-05	0.00128	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CA1—esophageal cancer	9.74e-05	0.00126	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—SLC10A2—esophageal cancer	9.74e-05	0.00126	CbGpPWpGaD
Cyproterone acetate—NR3C1—Glucocorticoid receptor regulatory network—TP53—esophageal cancer	9.7e-05	0.00126	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—MYC—esophageal cancer	9.55e-05	0.00124	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	9.54e-05	0.00124	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—EP300—esophageal cancer	9.43e-05	0.00122	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	9.34e-05	0.00121	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	9.08e-05	0.00118	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NOTCH2—esophageal cancer	8.95e-05	0.00116	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CA2—esophageal cancer	8.91e-05	0.00116	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	8.7e-05	0.00113	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—HIST1H2BM—esophageal cancer	8.65e-05	0.00112	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ADH7—esophageal cancer	8.28e-05	0.00107	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PLCE1—esophageal cancer	8.28e-05	0.00107	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—MYC—esophageal cancer	8.22e-05	0.00107	CbGpPWpGaD
Cyproterone acetate—NR3C1—SIDS Susceptibility Pathways—EP300—esophageal cancer	8.1e-05	0.00105	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—EGFR—esophageal cancer	8.04e-05	0.00104	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	7.91e-05	0.00103	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Breast Cancer Pathway—TP53—esophageal cancer	7.84e-05	0.00102	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	7.74e-05	0.001	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NR1I2—esophageal cancer	7.65e-05	0.000993	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—SMAD4—esophageal cancer	7.52e-05	0.000976	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—NOTCH1—esophageal cancer	7.3e-05	0.000948	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ADH1B—esophageal cancer	7.26e-05	0.000942	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—TYMP—esophageal cancer	6.94e-05	0.0009	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CYP26A1—esophageal cancer	6.75e-05	0.000876	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Integrated Breast Cancer Pathway—TP53—esophageal cancer	6.75e-05	0.000876	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	6.72e-05	0.000872	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—PSME1—esophageal cancer	6.71e-05	0.000871	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—PSME2—esophageal cancer	6.71e-05	0.000871	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—CREBBP—esophageal cancer	6.62e-05	0.00086	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ALOX15—esophageal cancer	6.58e-05	0.000854	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—HIST1H2BM—esophageal cancer	6.57e-05	0.000852	CbGpPWpGaD
Cyproterone acetate—AR—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	6.5e-05	0.000843	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—NOTCH3—esophageal cancer	6.33e-05	0.000822	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTO1—esophageal cancer	6.27e-05	0.000814	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—TPI1—esophageal cancer	6.27e-05	0.000814	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ALDOB—esophageal cancer	6.02e-05	0.000781	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GAPDH—esophageal cancer	5.79e-05	0.000752	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CRABP1—esophageal cancer	5.74e-05	0.000745	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—NOTCH2—esophageal cancer	5.68e-05	0.000737	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	5.54e-05	0.000719	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GNG7—esophageal cancer	5.46e-05	0.000708	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ALDH2—esophageal cancer	5.11e-05	0.000664	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—PSME2—esophageal cancer	5.09e-05	0.000661	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—PSME1—esophageal cancer	5.09e-05	0.000661	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	5.02e-05	0.000652	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—GSTT1—esophageal cancer	4.87e-05	0.000631	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CYP2A6—esophageal cancer	4.81e-05	0.000624	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NOTCH3—esophageal cancer	4.81e-05	0.000624	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.79e-05	0.000622	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—SMAD4—esophageal cancer	4.77e-05	0.000619	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTGS1—esophageal cancer	4.56e-05	0.000592	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ENO1—esophageal cancer	4.56e-05	0.000592	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PSME2—esophageal cancer	4.49e-05	0.000583	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PSME1—esophageal cancer	4.49e-05	0.000583	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NOTCH2—esophageal cancer	4.31e-05	0.000559	CbGpPWpGaD
Cyproterone acetate—AR—Generic Transcription Pathway—MYC—esophageal cancer	3.93e-05	0.00051	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.92e-05	0.000509	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CYP1B1—esophageal cancer	3.88e-05	0.000503	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—SMAD4—esophageal cancer	3.62e-05	0.00047	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—NOTCH1—esophageal cancer	3.52e-05	0.000456	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—HMOX1—esophageal cancer	3.33e-05	0.000432	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.26e-05	0.000423	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—ABCB1—esophageal cancer	3.19e-05	0.000414	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—CREBBP—esophageal cancer	3.19e-05	0.000414	CbGpPWpGaD
Cyproterone acetate—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	2.98e-05	0.000387	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—NOTCH1—esophageal cancer	2.67e-05	0.000346	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—CREBBP—esophageal cancer	2.42e-05	0.000314	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.41e-05	0.000313	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—CREBBP—esophageal cancer	2.13e-05	0.000277	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—NOS3—esophageal cancer	1.91e-05	0.000248	CbGpPWpGaD
Cyproterone acetate—AR—Gene Expression—MYC—esophageal cancer	1.89e-05	0.000246	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PTGS2—esophageal cancer	1.75e-05	0.000227	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—EP300—esophageal cancer	1.45e-05	0.000189	CbGpPWpGaD
Cyproterone acetate—NR3C1—Gene Expression—MYC—esophageal cancer	1.44e-05	0.000186	CbGpPWpGaD
Cyproterone acetate—CYP19A1—Metabolism—PIK3CA—esophageal cancer	1.07e-05	0.000139	CbGpPWpGaD
